- Centers & Specialties
- Clinical Interests
- Breast cancer
- Targeted therapies
- Medical Education
- MBBS, All India Institute of Medical Sciences
- MPH, University of Iowa College of Public Health
- Residency, All India Institute of Medical Sciences|Residency, Mayo Clinic
- Fellowship, The Johns Hopkins Hospital
- Board Certifications
- Internal Medicine
- Medical Oncology
- Foreign Languages
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
- Bardia A, Hartmann LC, et al. Leisure time physical activity & risk of postmenopausal breast cancer. Arch Intern Med. 2006;166:2478-83.
- Bardia A, Barton DL, et al. Efficacy of complementary & alternative medicine therapies in relieving cancer pain: Systematic Review. J Clin Oncol. 2006;24:5457-64.
- Bardia A, Ebbert JO, et al. Association of aspirin & other NSAID use with cancer incidence and mortality among post menopausal women. J Natl Cancer Inst. 2007;99(11):881-9.
- Bardia A, Stearns V. Personal Breast. Breast Cancer Res Treat. Editorial. 2010;120(2):437-9.
- Bardia A, Stearns V. Personalized Tamoxifen. Clin Cancer Res. Editorial. 2010;16(17):4308-10.
Does efficacy require toxicity, or is it time to reconsider presurgical endocrine therapy for estrogen-receptor-positive breast cancer?
Neoadjuvant endocrine therapy – designed to reduce the size of breast tumors before surgical removal – appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer side effects.
Mass. General study identifies genomic differences between breast cancers of African American and white women
A study from investigators at the MGH Cancer Center has, for the first time, identified genomic differences between the breast tumors of African American and white women, differences that could contribute to the recognized differences in recurrence rate and survival.
55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-726-6500
Phone 2: 617-724-4800